The treatment and outcomes of patients younger than 50 years (young adults
[YAs]) with pancreatic cancer
are largely unknown. We evaluated the presentation, treatment, and outcomes of these patients.
The National Cancer Database was analyzed. Univariate and multivariate Cox proportional hazards models were performed to identify variables associated with overall survival.
A total of 124,442 patients with pancreatic cancer
were identified, with 9657 between 18 and 50 years of age. Mean age was 45.4 years (standard deviation, 4.6 years). About 30.9% of YA patients and 25% of patients older than 50 years underwent resection of the primary tumor. Survival advantage was seen for patients 18 to 39 years (hazard ratio, 1.14; 95% confidence interval, 1.07–1.23; P
< 0.001). This age advantage was similar across all the racial groups. Overall, YAs treated between 2009 and 2013 had higher survival rates compared with 2004 to 2008 (hazard ratio, 0.85; 95% confidence interval, 0.81–0.89; P
< 0.001). This survival improvement was highest in American Indians and Asian/Pacific Islanders (16.6% vs 6.5%), African Americans (10.6% vs 8.5%), and Hispanics (14.5% vs 12.6%).
Survival of YAs with pancreatic cancer
patients is superior to older patients and has improved over time, especially in minority populations.